New als medication offers infusion of hope | va houston health care | veterans affairs

A Marine Corps Veteran got an infusion of hope this week when he became the second patient in the state of Texas and the first Veteran in the country to receive a groundbreaking drug aimed

at slowing the progression of amyotrophic lateral sclerosis (ALS). The new ALS medication, Qalsody, was approved by the FDA in April of this year.  Roy Swearingen, 65, from Cypress, TX,

received the medication at the Michael E. DeBakey VA Medical Center in Houston and feels optimistic about the drug’s benefits.   “I am hoping for the best and grateful to be able to get this

new medication,” Swearingen said. “My VA doctors told me about the research into this drug and when it became FDA-approved they were right on top of getting me started on it as soon as

possible.  I can’t thank them enough.” Qalsody is used for the treatment of a rare form of ALS in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, said Dr. James Orengo

MD PhD,  Director of the Houston VA ALS Center.   “About 1-2 percent of ALS patients have the SOD1 gene, making them eligible for this new medication,” Orengo said.   “This is the first

approved treatment to target a genetic cause of ALS and we are thrilled to offer it to Mr. Swearingen and other eligible Veterans.”  Swearingen was diagnosed with ALS a little over a year

ago and according to his wife, Sally, the availability of a new medication means the world to his entire family.   “We are very hopeful that we will see an improvement or at least a slowing

of the ALS symptoms as a result of the new medication,” she said.   “We have a three year old son who wants to know his father.” ALS, also known as Lou Gehrig’s disease, is a neurological

disease that causes degeneration of nerve cells in the brain and spinal cord leading to muscle weakness, atrophy, and loss of function. ALS ultimately robs a person of the ability to walk,

talk, eat, and breath. The ALS Association says over 5,000 people are diagnosed with the disease every year and most people that develop ALS are between the ages of 40 to 70 years old.  

Early diagnosis of ALS is very important, especially when it comes to Veterans, Orengo said. “Although there currently is no cure, early detection and expert clinical care can provide

optimal quality of life through a total body and wholistic management of symptoms,” he said.  “Research tells us that Veterans are at greater risk of being diagnosed with ALS than those with

no history of military service.  At the VA, we are determined to make sure our Veterans have access to the latest available medications and treatments of ALS symptoms.”   Houston VA offers

Veterans with ALS a state of the art multi-disciplinary team approach to their care in a specialized ALS Center, said Dr. Pitchaiah Mandava MD PhD, chief of neurology.   The Houston VA ALS

team, which also includes Dr. Kasra Rahbar MD, a Neurointerventionalist and Ms. Richel Aliboso, NP, is thrilled to be able to offer Qalsody as an option for ALS Veterans.     “This is an

exceptional example of personalized medicine that showcases the VA’s agility in offering cutting edge therapy to Veterans in a timely manner,” Mandava said.   For Sally Swearingen, her

husband’s ALS diagnosis is one of the biggest challenges of her life. Born and raised in Iraq, Sally has lived through three wars and is determined to support her husband in the fight

against the health and life challenges ALS presents. “Getting an ALS diagnosis has been devastating but in my gut I know the right thing to do is to try and fight it with the latest

medications and the best medical care,” she said. “This new medication and the VA is offering us hope and that’s what keeps us going."